Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk

Lung Cancer

Volumn 70, Issue 1, 2010, Pages 14-21

  Li, Yafei ^a   Sun, Zhifu ^a   Wu, Yanhong ^a   Babovic Vuksanovic, Dusica ^a   Li, Yan ^a   Cunningham, Julie M ^a   Pankratz, Vernon S ^a   Yang, Ping ^a  

^a Mayo Clinic   (United States)

Author keywords

Cystic fibrosis transmembrane conductance regulator; Genetic variation; Lung cancer

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77956190340     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.01.005     Document Type: Article

References (33)

1. Zielenski J., Tsui L.C. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 1995, 29:777-807.
2. Durno C., Corey M., Zielenski J., Tullis E., Tsui L.C., Durie P. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology 2002, 123:1857-1864.
3. Warren N., Holmes J.A., al-Jader L., West R.R., Lewis D.C., Padua R.A. Frequency of carriers of cystic fibrosis gene among patients with myeloid malignancy and melanoma. BMJ 1991, 302:760-761.
4. Neglia J.P., FitzSimmons S.C., Maisonneuve P., Schoni M.H., Schoni-Affolter F., Corey M., et al. The risk of cancer among patients with cystic fibrosis. N Engl J Med 1995, 332:494-499.
5. McWilliams R., Highsmith W.E., Rabe K.G., de Andrade M., Tordsen L.A., Holtegaard L.M., et al. Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut 2005, 54:1661-1662.
6. Padua R.A., Warren N., Grimshaw D., Smith M., Lewis C., Whittaker J., et al. The cystic fibrosis delta F508 gene mutation and cancer. Hum Mutat 1997, 10:45-48.
7. Southey M.C., Batten L., Andersen C.R., McCredie M.R., Giles G.G., Dite G., et al. CFTR deltaF508 carrier status, risk of breast cancer before the age of 40 and histological grading in a population-based case-control study. Int J Cancer 1998, 79:487-489.
8. Abraham E.H., Vos P., Kahn J., Grubman S.A., Jefferson D.M., Ding I., et al. Cystic fibrosis hetero- and homozygosity is associated with inhibition of breast cancer growth. Nat Med 1996, 2:593-596.
9. Qiao D., Yi L., Hua L., Xu Z., Ding Y., Shi D., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene 5T allele may protect against prostate cancer: a case-control study in Chinese Han population. J Cyst Fibros 2008, 7:210-214.
10. Yang P., Sun Z., Krowka M.J., Aubry M.C., Bamlet W.R., Wampfler J.A., et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008, 168:1097-1103.
11. Yang P., Wentzlaff K.A., Katzmann J.A., Marks R.S., Allen M.S., Lesnick T.G., et al. Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev 1999, 8:461-465.
12. Yang P., Allen M.S., Aubry M.C., Wampfler J.A., Marks R.S., Edell E.S., et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005, 128:452-462.
13. Taniguchi K., Yang P., Jett J., Bass E., Meyer R., Wang Y., et al. Polymorphisms in the promoter region of the neutrophil elastase gene are associated with lung cancer development. Clin Cancer Res 2002, 8:1115-1120.
14. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
15. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
16. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002, 70:425-434.
17. Lake S.L., Lyon H., Tantisira K., Silverman E.K., Weiss S.T., Laird N.M., et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003, 55:56-65.
18. Yu Z., Schaid D.J. Application of sequential haplotype scan methods to case-control data. BMC Proc 2007, 1(Suppl. 1):S21.
19. Yu Z., Schaid D.J. Sequential haplotype scan methods for association analysis. Genet Epidemiol 2007, 31:553-564.
20. Sheppard D.N., Welsh M.J. Structure and function of the CFTR chloride channel. Physiol Rev 1999, 79:S23-45.
21. Schwiebert E.M., Benos D.J., Egan M.E., Stutts M.J., Guggino W.B. CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 1999, 79:S145-S166.
22. Kerem B., Rommens J.M., Buchanan J.A., Markiewicz D., Cox T.K., Chakravarti A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
23. The Cystic Fibrosis Genetic Analysis Consortium Population variation of common cystic fibrosis mutations. Hum Mutat 1994, 4:167-177.
24. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000, 67:117-133.
25. Tsui L.C. The spectrum of cystic fibrosis mutations. Trends Genet 1992, 8:392-398.
26. Cuppens H., Lin W., Jaspers M., Costes B., Teng H., Vankeerberghen A., et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 1998, 101:487-496.
27. Moribe T., Iizuka N., Miura T., Kimura N., Tamatsukuri S., Ishitsuka H., et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer 2009, 125:388-397.
28. Yu J., Zhu T., Wang Z., Zhang H., Qian Z., Xu H., et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007, 13:7296-7304.
29. Cohen J.C., Lundblad L.K., Bates J.H., Levitzky M., Larson J.E. The " Goldilocks effect" in cystic fibrosis: identification of a lung phenotype in the cftr knockout and heterozygous mouse. BMC Genet 2004, 5:21.
30. Foster C.S., Cornford P., Forsyth L., Djamgoz M.B., Ke Y. The cellular and molecular basis of prostate cancer. BJU Int 1999, 83:171-194.
31. Lemonnier L., Shuba Y., Crepin A., Roudbaraki M., Slomianny C., Mauroy B., et al. Bcl-2-dependent modulation of swelling-activated Cl- current and ClC-3 expression in human prostate cancer epithelial cells. Cancer Res 2004, 64:4841-4848.
32. Lader A.S., Prat A.G., Jackson G.R., Chervinsky K.L., Lapey A., Kinane T.B., et al. Increased circulating levels of plasma ATP in cystic fibrosis patients. Clin Physiol 2000, 20:348-353.
33. Humez S., Monet M., van Coppenolle F., Delcourt P., Prevarskaya N. The role of intracellular pH in cell growth arrest induced by ATP. Am J Physiol Cell Physiol 2004, 287:C1733-C1746.